Aspirin

Aspirin use for primary atherosclerotic CVD prevention continues to be prevalent in adults aged 70 years or older despite contrary guideline recommendations, according to data published in the American Journal of Preventive Cardiology.

Primary care clinics that implemented seven evidence-based strategies saw significant improvements in cardiovascular-related clinical quality measures, data showed.

Dual antiplatelet therapy that combined aspirin with either ticagrelor or clopidogrel outperformed aspirin alone in minor ischemic stroke and transient ischemic attack, according to results of a network meta-analysis.

Ticagrelor added to low-dose aspirin reduced the risk for spontaneous MI, MI related to stent thrombosis and STEMI compared with placebo in patients with diabetes and CAD, according to a new analysis of the THEMIS trial.

The Healio and Cardiology Today Editors have compiled the top news from November.

During the COVID-19 pandemic lockdown, patients reported an increase in stress and decrease in overall mood and physical activity, according to a recent study. It was the top story in cardiology last week.

Among patients with predisposing factors for HF, aspirin use was associated with a 26% increased risk for HF development, researchers reported in ESC Heart Failure.

DAPT for 1 months or 12 months in patients with ACS undergoing PCI with a cobalt-chromium everolimus-eluting stent (Xience family, Abbott Vascular).

Daily low-dose aspirin use over 7 years did not affect the risk for incident dementia or cognitive decline in U.K. adults with type 2 diabetes, according to new data from the ASCEND trial.

Daily low-dose aspirin use over 7 years did not affect the risk for incident dementia or cognitive decline in U.K. adults with type 2 diabetes, according to new data from the ASCEND trial.